Back to Research

Organization profile

Lonza

Lonza is a leading global contract development and manufacturing organization (CDMO) that provides services to the pharmaceutical, biotech, and nutrition industries. The company offers a wide range of services including the development and commercial manufacturing of biologics, small molecules, and cell and gene therapies, supporting customers across the entire drug development lifecycle.

Visp, Switzerland

Overview

1. Executive Summary (Confidence: High)

In 2024, Lonza initiated a pivotal "One Lonza" strategy aimed at refocusing the organization on its core CDMO business and strengthening its foundation for long-term value creation. Led by new CEO Wolfgang Wienand and Chair Jean-Marc Huët, the company reported annual sales of CHF 6. billion and a robust CORE EBITDA margin of 29.0%. A cornerstone of its 2024 performance was the strategic acquisition of Genentech’s large-scale biologics manufacturing site in Vacaville, US, from Roche for USD 1. billion, significantly expanding its mammalian manufacturing network. Furthermore, Lonza announced its intent to exit the Capsules & Health Ingredients (CHI) business to prioritize high-growth "Specialized Modalities" and "Advanced Synthesis" platforms.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.